Previously, Dr. Miller was a Professor of Chemistry from February 2013 to March 2022 and Assistant Professor of Chemistry from June 2008 to February 2013 at the California Institute of Technology. He currently serves as a director of Veracyte, Inc., a genomic diagnostics company. Dr. Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University, an M.Phil. in Theoretical Chemistry from University College London and a Ph.D. in Theoretical Chemistry from the University of Oxford.

Previously, Dr. Manby was a Professor of Theoretical Chemistry from August 2010 to March 2022 at the University of Bristol. He holds a B.Sc. and Ph.D. in Chemistry from the University of York.

He served as the Chief Medical Officer and Head of Global Drug Development at Bristol-Myers Squibb Company from June 2019 to November 2025 and has since served as a consultant in the pharmaceutical industry. Dr. Hirawat has served on the board of directors of Pacira Biosciences, Inc., a pharmaceutical company, since January 2026 and currently serves on the boards of directors of several privately-held companies. He holds an M.B.B.S. from the Sawai Man Singh Medical College and completed his internal medicine residency and medical oncology training at North Shore University Hospital.

He has served as a Managing Partner at Ascenta Capital, a venture capital firm he co-founded, since January 2023. From April 2019 to April 2022, Dr. Rachlin served as a Managing Director at Blackstone Life Sciences, a private investment platform. From June 2015 to March 2019, he served as Head of Strategy at Moderna, Inc., a pharmaceutical and biotechnology company. He was a Principal at Bain Capital Ventures from September 2012 to May 2015, and began his career at McKinsey & Company. He holds an A.B. in Biochemistry and Japanese from Harvard College and an M.D. and M.B.A. from Harvard Medical School and Harvard Business School.

He has served as a director of Daré Bioscience, Inc. since January 2014, Fate Therapeutics, Inc. since December 2011, and Neurocrine Biosciences, Inc. since February 2010. He has served as chair of those boards since July 2019, December 2011, and May 2011, respectively. Dr. Rastetter previously served as the Interim Chief Executive Officer and Chairman of Grail, Inc., and as a member of the board of directors of Regulus Therapeutics, Inc. from April 2013 until its acquisition by Novartis AG in June 2025. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013. He was Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and was Executive Chairman of Biogen Idec, Inc. from November 2003 through 2005. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and an M.A. and Ph.D. in Chemistry from Harvard University.

She served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company, from May 2012 until October 2020. Prior to joining Ultragenyx, Ms. Sharp served as Vice President and Chief Financial Officer of Agenus Inc., an immuno-oncology company, from 2006 to 2012. She held finance, corporate development and corporate strategy roles at Agenus from 2003 to 2006, and various roles at Elan Pharmaceuticals from 1998 to 2003. Prior to Elan, Ms. Sharp was a management consultant at McKinsey & Company, as well as an investment banker at Goldman Sachs. Ms. Sharp currently serves on the boards of directors of BeOne Medicines Ltd. since September 2024, Neurocrine Biosciences, Inc. since February 2020, Organon & Co. since May 2021 and Septerna, Inc. since January 2024. She previously served on the boards of directors of Mirati Therapeutics, Inc., prior to its acquisition by BMS from March 2021 to January 2024, Sutro Biopharma, Inc. from November 2018 to April 2023, and Precision BioSciences, Inc. from December 2018 to June 2022, among others. She holds an A.B. from Harvard University and an M.B.A. from Harvard Business School.

She joined Nektar Therapeutics, Inc. in January 2015 and has served in various executive roles including as Senior Vice President, Chief Medical Officer since September 2025, as Senior Vice President, Chief Medical/Development Officer from May 2022 to February 2025, as Senior Vice President, Executive Clinical Fellow from April 2020 to April 2022 and as Senior Vice President, Chief Medical Officer from November 2017 to May 2020. Dr. Tagliaferri previously served on the boards of directors of Enzo Biochem, Inc. from November 2020 to August 2024, RayzeBio, Inc. from September 2021 to February 2024, and Y-mAbs Therapeutics, Inc. from March 2024 to July 2025. She holds a B.S. in Agricultural Economics and Business Management from Cornell University, a Post-Baccalaureate Degree in Science from Bryn Mawr College, an M.S. in Oriental Medicine from American College of Traditional Chinese Medicines, and an M.D. from the University of California, San Francisco.

He has served as a Managing Partner of Catalio Capital Management, LP, an investment firm he co-founded, specializing in the biomedical technology and life sciences sectors, since June 2020. From January 2016 to December 2020, he served as a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun-out of T. Rowe Price. Dr. Vogelstein currently serves on the boards of directors of several privately-held companies. He holds a B.S. in Bio-Electrical Engineering from Brown University and a Ph.D. in Biomedical Engineering from the Johns Hopkins University School of Medicine.

He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co-founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA).